Siemens Agrees to Buy Dotmatics for $5.1B, Expanding AI Portfolio to Life Sciences -- Update

Dow Jones
04-03
 

By Kelly Cloonan

 

Siemens has agreed to acquire Dotmatics for $5.1 billion, a combination the companies said would use artificial intelligence to speed up development cycles and help make breakthroughs in the life-sciences space.

Dotmatics provides software connecting science, data and decision making to support research and development in the life-sciences industry.

The deal would combine Dotmatics's applications with Siemens's manufacturing, industrial-simulation and AI capabilities, connecting development from the research-and-development stage all the way through manufacturing. Siemens said that Dotmatics will increase its total addressable market within the industrial software industry by $11 billion.

The deal aligns with the Munich company's aims to accelerate innovation across industries.

"Artificial intelligence has emerged as a transformative force across various industries, and its application in life sciences is becoming increasingly important," Siemens Chief Executive Roland Busch said.

The deal will be financed primarily through the sale of shares in listed companies, including Siemens Healthineers, Siemens said.

Dotmatics, which is currently backed by investment firm Insight Partners, is expected to generate more than $300 million in revenue this fiscal year. Siemens said the company is highly profitable and has an adjusted Ebitda--or earnings before interest, taxes, depreciation and amortization--margin of more than 40%

Siemens expects medium-term revenue synergies of around $100 million a year, which would pick up to over $500 million a year in the long term. The deal will be immediately accretive to Siemens's growth, Ebitda margin and free cash flow before considering any synergies.

Siemens expects the deal to close in the first half of fiscal 2026.

 

Write to Kelly Cloonan at kelly.cloonan@wsj.com

 

(END) Dow Jones Newswires

April 02, 2025 15:45 ET (19:45 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10